CSIMarket
 


Kymera Therapeutics Inc   (KYMR)
Other Ticker:  
 

Kymera Therapeutics Inc 's Quick Ratio

KYMR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




KYMR Quick Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Current Liabilities Change 38.2 % 27.15 % 61.58 % 107.77 % -
Y / Y Cash & cash equivalent Change 34.2 % 17.62 % 42.07 % 82.54 % -
Quick Ratio MRQ 15.19 16.09 17.59 21.78 15.64
Overall Ranking # # # # #
Seq. Current Liabilities Change 30.12 % 1.94 % -2.87 % 7.27 % 19.72 %
Seq. Cash & cash equivalent Change 22.84 % -6.77 % -21.55 % 49.37 % 7.67 %



Quick Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 15.19 above Kymera Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry Kymera Therapeutics Inc booked the highest Quick Ratio than Kymera Therapeutics Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Quick Ratio?
What are KYMR Segments?
See Quick Ratio KYMR on the trailing twelve month basis
Quick Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Kymera Therapeutics Inc 's Current Liabilities $ 32 Millions Visit KYMR's Balance sheet
Kymera Therapeutics Inc 's Cash & cash equivalent $ 482 Millions Visit KYMR's Balance sheet
Source of KYMR's Sales Visit KYMR's Sales by Geography


Cumulative Kymera Therapeutics Inc 's Quick Ratio

KYMR's Quick Ratio for the trailling 12 Months

KYMR Quick Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Current Liabilities TTM Growth 38.2 % 27.15 % 61.58 % 107.77 % -
Y / Y Cash & cash equivalent TTM Growth 34.2 % 17.62 % 42.07 % 82.54 % -
Quick Ratio TTM 17.5 17.82 18.19 18.7 18.65
Total Ranking TTM # 474 # 829 # 978 # 872 #
Seq. Current Liabilities TTM Growth 30.12 % 1.94 % -2.87 % 7.27 % 19.72 %
Seq. Cash & cash equivalent TTM Growth 22.84 % -6.77 % -21.55 % 49.37 % 7.67 %


TTM Quick Ratio Comment
On the trailing twelve months basis Due to growth in Current Liabilities in the III. Quarter to $31.73 millions, average cumulative Quick Ratio decreased to 17.5 below the Kymera Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 87 other companies have achieved higher Quick Ratio than Kymera Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. 474.

Explain Quick Ratio?
What are KYMR Segments?
See Quick Ratio KYMR on the trailing twelve month basis

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 88
Healthcare Sector # 324
Within the Market # 474


TTM Quick Ratio Statistics
High Average Low
5.07 3.83 2.78
(Sep 30 2022)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Nautilus Biotechnology Inc   40.09 $ 257.970  Millions$ 6.434  Millions
Hillevax Inc   33.83 $ 292.060  Millions$ 8.633  Millions
Seer Inc   32.03 $ 436.064  Millions$ 13.616  Millions
Singular Genomics Systems Inc   31.13 $ 263.840  Millions$ 8.475  Millions
Acumen Pharmaceuticals Inc   30.27 $ 200.194  Millions$ 6.613  Millions
Protara Therapeutics Inc   25.95 $ 96.317  Millions$ 3.711  Millions
Astrotech Corp  25.93 $ 48.948  Millions$ 1.888  Millions
Arca Biopharma Inc   22.68 $ 43.939  Millions$ 1.937  Millions
Athira Pharma Inc   21.53 $ 220.962  Millions$ 10.264  Millions
Talaris Therapeutics Inc   21.15 $ 193.869  Millions$ 9.168  Millions
Rewalk Robotics Ltd   20.48 $ 74.027  Millions$ 3.614  Millions
Celldex Therapeutics inc   19.86 $ 323.471  Millions$ 16.287  Millions
Vor Biopharma Inc   18.53 $ 136.067  Millions$ 7.345  Millions
Fusion Pharmaceuticals Inc   17.15 $ 205.481  Millions$ 11.981  Millions
Icosavax Inc   16.99 $ 221.399  Millions$ 13.033  Millions
4d Molecular Therapeutics Inc   16.79 $ 227.715  Millions$ 13.564  Millions
Organovo Holdings Inc   16.72 $ 23.220  Millions$ 1.389  Millions
Vaxcyte Inc   16.02 $ 362.226  Millions$ 22.614  Millions
Replimune Group Inc   15.80 $ 371.820  Millions$ 23.537  Millions
Kymera Therapeutics Inc   15.19 $ 481.908  Millions$ 31.729  Millions
Cardiff Oncology inc   15.10 $ 114.303  Millions$ 7.571  Millions
Candel Therapeutics Inc   14.17 $ 77.183  Millions$ 5.446  Millions
Krystal Biotech Inc   14.07 $ 394.420  Millions$ 28.032  Millions
Entera Bio Ltd   13.46 $ 14.323  Millions$ 1.064  Millions
Tracon Pharmaceuticals inc   13.28 $ 17.037  Millions$ 1.283  Millions
Century Therapeutics inc   13.23 $ 355.859  Millions$ 26.907  Millions
Immunovant Inc   12.77 $ 405.773  Millions$ 31.784  Millions
Allovir Inc   12.75 $ 264.107  Millions$ 20.719  Millions
Quince Therapeutics Inc   12.65 $ 62.534  Millions$ 4.945  Millions
Talis Biomedical Corporation  12.64 $ 143.783  Millions$ 11.378  Millions

Date modified: 2022-11-06T04:53:19+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PMVC's Profile

Stock Price

PMVC's Financials

Business Description

Fundamentals

Charts & Quotes

PMVC's News

Suppliers

PMVC's Competitors

Customers & Markets

Economic Indicators

PMVC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071